$42.70
0.23% yesterday
NYSE, May 20, 10:10 pm CET
ISIN
NL0012169213
Symbol
QGEN

QIAGEN NV Stock price

$42.70
+2.22 5.48% 1M
-0.59 1.37% 6M
-3.10 6.77% YTD
-4.07 8.70% 1Y
-5.30 11.05% 3Y
-3.04 6.66% 5Y
+15.00 54.15% 10Y
NYSE, Closing price Tue, May 20 2025
-0.10 0.23%
ISIN
NL0012169213
Symbol
QGEN
Sector

Key metrics

Market capitalization $9.23b
Enterprise Value $9.67b
P/E (TTM) P/E ratio 102.30
EV/FCF (TTM) EV/FCF 19.13
EV/Sales (TTM) EV/Sales 4.83
P/S ratio (TTM) P/S ratio 4.61
P/B ratio (TTM) P/B ratio 2.71
Dividend yield 3.64%
Last dividend (FY25) $1.55
Revenue growth (TTM) Revenue growth 3.31%
Revenue (TTM) Revenue $2.00b
EBIT (operating result TTM) EBIT $521.88m
Free Cash Flow (TTM) Free Cash Flow $505.68m
Cash position $963.45m
EPS (TTM) EPS $0.42
P/E forward 21.09
P/S forward 4.49
EV/Sales forward 4.71
Short interest 3.47%
Show more

Is QIAGEN NV a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

QIAGEN NV Stock Analysis

Unlock Scores for Free

Analyst Opinions

24 Analysts have issued a QIAGEN NV forecast:

13x Buy
54%
11x Hold
46%

Analyst Opinions

24 Analysts have issued a QIAGEN NV forecast:

Buy
54%
Hold
46%

Financial data from QIAGEN NV

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
2,003 2,003
3% 3%
100%
- Direct Costs 731 731
0% 0%
37%
1,271 1,271
5% 5%
63%
- Selling and Administrative Expenses 371 371
2% 2%
19%
- Research and Development Expense 186 186
5% 5%
9%
715 715
10% 10%
36%
- Depreciation and Amortization 193 193
7% 7%
10%
EBIT (Operating Income) EBIT 522 522
18% 18%
26%
Net Profit 94 94
72% 72%
5%

In millions USD.

Don't miss a Thing! We will send you all news about QIAGEN NV directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

QIAGEN NV Stock News

Positive
Seeking Alpha
6 days ago
QGEN has a relatively well-diversified portfolio across four segments on Sample Technologies, PCR/NA Amplification, Genomics/NGS, and Diagnostic Solutions. Their QIAstat-Dx's multiplex syndromic panels and QuantiFERON TB tests drive double-digit growth. Plus, QGEN seems to have a good competitive position across several niches. Also, QGEN's recent acquisition of Genoox and its AI-powered Frankl...
Neutral
Business Wire
8 days ago
VENLO, the Netherlands & TEL AVIV, Israel--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has signed a definitive agreement to acquire Genoox, a provider of AI-powered software that enables clinical labs to scale and accelerate the processing of complex genetic tests. The acquisition adds Franklin, Genoox's flagship cloud-based community...
Neutral
Seeking Alpha
12 days ago
Qiagen N.V. (NYSE:QGEN ) Q1 2025 Earnings Conference Call May 8, 2025 9:00 AM ET Company Participants John Gilardi - Vice President, Head of Corporate Communications & Investor Relations Thierry Bernard - Chief Executive Officer Roland Sackers - Chief Financial Officer Conference Call Participants Dan Leonard - UBS Doug Schenkel - Wolfe Research Patrick Donnelly - Citi Tycho Peterson - Jefferie...
More QIAGEN NV News

Company Profile

QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.

Head office Netherlands
CEO Thierry Bernard
Employees 5,765
Founded 1996
Website www.qiagen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today